Primary liver cancer after surgery
Conditions
Interventions
Experimental group:Regular postoperative therapy is the same as the control group. Intake of capecitabine: 1000mg/m2, Bid, oral intake in 30 minutes after meals.
Control group:Regular postoperative therapy includes medicines for liver supporting and preventive interventional treatment and immunotherapy.
Sponsors
Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Those who haven't participate in other clinical trials or chemotherapy; 2. Liver function grade > Child B, whithout cancer embolus in the main portal veins or metastasis; 3. Age: 18-70 years old, no gender restrict; 4. Adjuvant therapyaccepted more than 6 months ago; 5. Pathologically diagnosed as hepatocellular carcinoma with qualitative data; 6. Liver function recovers to normal after surgery, Child Grade I, AFP 9.0g/dl, WBC>4000/ml, PLT>100000/ml; 8. GPT, GOT=70 scores; 9. Predicted survival > 6 months; 10. Participants sign the informed consent form before enrollment.
Exclusion criteria
Exclusion criteria: 1. Age 75years; 2. Pregnant or breast-feeding women; 3. Allergic or seriously response to 5-Fu; 4. Peripheral and central nervous abnormality and psychiatric disease; 5. Abnormal ECG or evident heart disease; 6. Severe infection, sepsis, metabolic disturbance or diabetes; 7. Active digestive ulcer needs treating or absorption disorder; 8. Malignant tumor of other sites in recent 5 years or meatastasis to cerebrum and bone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function, blood routine, AFP, B ultrasound, take CT or MRI periodically and DSA if necessary.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and renal function, adverse enent; | — |
Countries
China
Contacts
Public ContactShen Feng, Yong Xia
Outcome results
None listed